We are live on
!
Find out more
BC
Birchview Capital Portfolio holdings
AUM
$176M
1-Year Est. Return
95.04%
This Fund
S&P 500
This Quarter
Est. Return
-0.07%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$147M
AUM Growth
-$4.71M
(-3.1%)
Cap. Flow
+$154K
Cap. Flow
% of AUM
0.1%
Top 10 Holdings %
Top 10 Hldgs %
83.52%
Holding
56
New
7
Increased
6
Reduced
13
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Karyopharm Therapeutics
KPTI
|
+$824K |
| 2 |
Nektar Therapeutics
NKTR
|
+$730K |
| 3 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$645K |
| 4 |
InflaRx
IFRX
|
+$553K |
| 5 |
CMTA
Clementia Pharmaceuticals Inc.
CMTA
|
+$486K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.91M |
| 2 |
XLRN
Acceleron Pharma
XLRN
|
+$474K |
| 3 |
Corcept Therapeutics
CORT
|
+$444K |
| 4 |
SHPG
Shire pic
SHPG
|
+$403K |
| 5 |
Solid Biosciences
SLDB
|
+$287K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.63% |
| 2 | Energy | 3.26% |
| 3 | Consumer Staples | 0.26% |
| 4 | Industrials | 0.25% |
| 5 | Consumer Discretionary | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $54.5M | 37.04% |
686,181
-23,000
| -3% | -$1.91M |
|
|
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
| $48.7M | 33.1% |
218,380
| – | – |
|
3
Neurocrine Biosciences
NBIX
$17.2B
| $4.91M | 3.34% |
50,000
-2,400
| -5% | -$215K |
|
|
CFRX
4
DELISTED
ContraFect Corporation
CFRX
| $2.38M | 1.61% |
1,344
-75
| -5% | -$110K |
|
5
QuidelOrtho
QDEL
$1.19B
| $2.26M | 1.54% |
33,975
| – | – |
|
|
ARRY
6
DELISTED
Array Biopharma Inc
ARRY
| $2.15M | 1.46% |
128,000
+16,000
| +14% | +$255K |
|
7
Ovintiv
OVV
$16.2B
| $2.12M | 1.44% |
32,460
+6,000
| +23% | +$376K |
|
8
EQT Corp
EQT
$31B
| $2.11M | 1.44% |
70,357
-7,348
| -9% | -$205K |
|
|
OXFD
9
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $2.03M | 1.38% |
157,303
-20,000
| -11% | -$270K |
|
|
VRML
10
DELISTED
Vermillion, Inc.
VRML
| $1.74M | 1.18% |
2,232,933
-130,000
| -6% | -$146K |
|
11
Vanda Pharmaceuticals
VNDA
$327M
| $1.68M | 1.14% |
88,000
| – | – |
|
|
SLNO
12
DELISTED
Soleno Therapeutics
SLNO
| $1.59M | 1.08% |
45,229
| – | – |
|
|
ALBO
13
DELISTED
Albireo Pharma Inc
ALBO
| $1.35M | 0.92% |
38,000
+14,000
| +58% | +$453K |
|
14
Atara Biotherapeutics
ATRA
$75.6M
| $1.25M | 0.85% |
1,360
+440
| +48% | +$473K |
|
|
SIEN
15
DELISTED
Sientra, Inc.
SIEN
| $1.24M | 0.84% |
6,330
| – | – |
|
|
ARNA
16
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $1.09M | 0.74% |
25,000
+15,000
| +150% | +$645K |
|
|
GTHX
17
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $956K | 0.65% |
22,000
| – | – |
|
18
Veracyte
VCYT
$4.72B
| $922K | 0.63% |
98,767
-20,000
| -17% | -$141K |
|
|
CMTA
19
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
| $895K | 0.61% |
68,000
+30,000
| +79% | +$486K |
|
|
20
Karyopharm Therapeutics
KPTI
$216M
| $850K | 0.58% |
+3,333
| New | +$824K |
|
|
21
Corcept Therapeutics
CORT
$9.72B
| $786K | 0.53% |
50,000
-25,500
| -34% | -$444K |
|
|
MASI
22
DELISTED
Masimo
MASI
| $781K | 0.53% |
8,000
| – | – |
|
|
WMGI
23
DELISTED
Wright Medical Group Inc
WMGI
| $779K | 0.53% |
30,000
| – | – |
|
24
Voyager Therapeutics
VYGR
$192M
| $645K | 0.44% |
33,000
| – | – |
|
25
Axogen
AXGN
$2.12B
| $603K | 0.41% |
12,000
-6,000
| -33% | -$264K |
|
Similar funds
RWA
BAM
TIM
TFCM
FPW
LWM
PFA
DAM
Birchview Capital's Q2 2018 Portfolio in Review
As of Q2 2018, Birchview Capital held 56 positions worth $147M, down 3.1% from $152M the previous quarter. Its ten largest holdings account for 84% of the portfolio.
Birchview Capital's Q2 2018 filing shows 7 new, 6 increased, 13 reduced and 3 closed positions. Its largest new stake was Karyopharm Therapeutics: 3,333 shares worth $850K. The largest sale was Celgene Corp, an estimated $1.91M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Energy and Consumer Staples.
- Birchview Capital's largest Q2 2018 buy was Karyopharm Therapeutics: 3,333 shares worth $850K.
- Birchview Capital added most to Arena Pharmaceuticals Inc in Q2 2018, an estimated $645K increase.
- Birchview Capital's biggest Q2 2018 reduction was Celgene Corp, cutting an estimated $1.91M.
- Birchview Capital fully exited Shire pic in Q2 2018, selling an estimated $403K.
- Birchview Capital's ten largest holdings make up 84% of its $147M portfolio in Q2 2018.
- Birchview Capital opened 7 new positions and closed 3 in Q2 2018.
- Birchview Capital's portfolio value fell 3.1% quarter-over-quarter to $147M.
Based on Birchview Capital's 13F filing for Q2 2018, filed 2 Aug 2018.